Comparison of anti-anaerobic antimicrobial strategies in cancer patients with febrile neutropenia and gastrointestinal symptoms
Open Access
- 8 September 2014
- journal article
- research article
- Published by Springer Nature in BMC Research Notes
- Vol. 7 (1) , 1-4
Abstract
The current study sought to compare 28-day mortality rates in cancer patients with febrile neutropenia (FN) and gastrointestinal (GI) symptoms who underwent monotherapy using an antibiotic with antipseudomonal and anti-anaerobic activity (piperacillin-tazobactam or a carbapenem) and a group treated with a combination of cefepime-metronidazole. We performed a prospective cohort study in a single tertiary hospital from October 2009 to August 2011. All consecutive adult cancer patients admitted with FN secondary to intensive chemotherapy and GI symptoms (abdominal pain, diarrhea or perianal pain) were evaluated. Kaplan-Meier curves were used for calculating time-dependent occurence of death. In total, 37 patients with FN and GI symptoms were evaluated (15 in monotherapy arm and 22 in the combination therapy arm). Treatment with combination cefepime and metronidazole resulted in a lower 28-day mortality rate compared with piperacillin-tazobactam or carbapenem monotherapy (0% versus 40%; log-rank P=0.002). Results of the present study suggest a significant reduction in mortality in cancer patients with FN and GI symptoms treated with combination cefepime-metronidazole therapy compared with monotherapy using agents with antipseudomonal and anti-anaerobic activity. Further randomized trials are warranted to confirm the superior results using combination therapy in patients with FN and GI symptoms.Keywords
This publication has 13 references indexed in Scilit:
- Cohort Study of the Impact of Time to Antibiotic Administration on Mortality in Patients with Febrile NeutropeniaAntimicrobial Agents and Chemotherapy, 2014
- Association between adherence to an antimicrobial stewardship program and mortality among hospitalised cancer patients with febrile neutropaenia: a prospective cohort studyBMC Infectious Diseases, 2014
- Population-based assessment of the incidence, risk factors, and outcomes of anaerobic bloodstream infectionsInfection, 2013
- Epidemiological characteristics of infections caused by Bacteroides, Prevotella and Fusobacterium species: A prospective observational studyAnaerobe, 2011
- Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2011
- Management of febrile neutropenia: ESMO Clinical Practice GuidelinesAnnals of Oncology, 2010
- Metronidazole Is Still the Drug of Choice for Treatment of Anaerobic InfectionsClinical Infectious Diseases, 2010
- A Randomized Prospective Study of Cefepime Plus Metronidazole with Imipenem-Cilastatin in the Treatment of Intra-abdominal InfectionsInfection, 2007
- Risk Factors for Anaerobic Bloodstream Infections in Bone Marrow Transplant RecipientsClinical Infectious Diseases, 2001
- A Randomized, Double-blind Clinical Trial Comparing Cefepime Plus Metronidazole With Imipenem-Cilastatin in the Treatment of Complicated Intra-abdominal InfectionsArchives of Surgery, 1997